Halit Eren Taskin1, Ahmet Kocael2, Pinar Kocael2, Kagan Zengin2, Muzaffer Al3, Volkan Sozer4, J N Buchwald5, T W McGlennon6, Hafize Uzun7. 1. Department of Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey. eren_taskin@hotmail.com. 2. Department of Surgery, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey. 3. Department of Surgery, Faculty of Medicine, Near East University, Nicosia, Turkey. 4. Department of Biochemistry, Yildiz Technical University, Istanbul, Turkey. 5. Division of Scientific Research Writing, Medwrite Medical Communications, Maiden Rock, WI, USA. 6. Statistical Analysis Division, McGlennon MotiMetrics, Maiden Rock, WI, USA. 7. Department of Medical Biochemistry, Faculty of Medicine, İstanbul Atlas University, Istanbul, Turkey.
Abstract
BACKGROUND: Early diagnosis of subclinical cardiovascular disease (CVD) in patients with morbid obesity is important. We investigated the effects of sleeve gastrectomy (SG) on serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1), oxidized LDL (oxLDL), and other metabolic and inflammatory parameters associated with atherosclerosis in patients with morbid obesity. METHODS: Body mass index (BMI) measurements and assays of metabolic and inflammatory markers were taken in patients in an SG surgery group and a healthy control group and compared at baseline and 12 months after SG. Correlations with changes in these parameters and variations in sLOX-1 were analyzed. RESULTS: Metabolic and inflammatory marker values in the surgery (n = 20) and control (n = 20) groups were significantly different at baseline (p < 0.001). The majority of surgery group biomarker levels significantly decreased with mean BMI loss (- 11.8 ± 9.0, p < 0.001) at 12 months, trending toward control group values. Baseline albumin level as well as percentage reductions in oxLDL and the cholesterol retention fraction (CRF) were found to be significantly correlated with percentage reduction in sLOX-1 at 12 months following SG. CONCLUSION: Metabolic and inflammatory biomarkers elevated at baseline significantly decreased after SG weight loss. Weight loss induced by SG may limit endothelial damage by reducing levels of oxLDL and LOX-1 as assessed by sLOX-1. These findings suggest that sLOX-1 may function as a marker of atherosclerotic disease states in patients with morbid obesity and that metabolic/bariatric surgery can play a meaningful role in CVD prevention.
BACKGROUND: Early diagnosis of subclinical cardiovascular disease (CVD) in patients with morbid obesity is important. We investigated the effects of sleeve gastrectomy (SG) on serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1), oxidized LDL (oxLDL), and other metabolic and inflammatory parameters associated with atherosclerosis in patients with morbid obesity. METHODS: Body mass index (BMI) measurements and assays of metabolic and inflammatory markers were taken in patients in an SG surgery group and a healthy control group and compared at baseline and 12 months after SG. Correlations with changes in these parameters and variations in sLOX-1 were analyzed. RESULTS: Metabolic and inflammatory marker values in the surgery (n = 20) and control (n = 20) groups were significantly different at baseline (p < 0.001). The majority of surgery group biomarker levels significantly decreased with mean BMI loss (- 11.8 ± 9.0, p < 0.001) at 12 months, trending toward control group values. Baseline albumin level as well as percentage reductions in oxLDL and the cholesterol retention fraction (CRF) were found to be significantly correlated with percentage reduction in sLOX-1 at 12 months following SG. CONCLUSION: Metabolic and inflammatory biomarkers elevated at baseline significantly decreased after SG weight loss. Weight loss induced by SG may limit endothelial damage by reducing levels of oxLDL and LOX-1 as assessed by sLOX-1. These findings suggest that sLOX-1 may function as a marker of atherosclerotic disease states in patients with morbid obesity and that metabolic/bariatric surgery can play a meaningful role in CVD prevention.
Authors: Jawahar L Mehta; Jiawei Chen; Paul L Hermonat; Francesco Romeo; Giuseppe Novelli Journal: Cardiovasc Res Date: 2005-12-01 Impact factor: 10.787
Authors: Srinivasan Beddhu; George A Kaysen; Guofen Yan; Mark Sarnak; Lawrence Agodoa; Daniel Ornt; Alfred K Cheung Journal: Am J Kidney Dis Date: 2002-10 Impact factor: 8.860
Authors: Martin Schillinger; Markus Exner; Wolfgang Mlekusch; Jasmin Amighi; Schila Sabeti; Oliver Schlager; Oswald Wagner; Erich Minar Journal: Thromb Haemost Date: 2004-03 Impact factor: 5.249